Ardelyx Investors Face November Deadline in Securities Class Action

The lawsuit alleges that Ardelyx repeatedly reaffirmed billion-dollar sales targets for IBSRELA and XPHOZAH while failing to disclose that payer-imposed prior authorization and step edit requirements were hindering new-patient starts. According to the complaint, management maintained these optimistic revenue forecasts for 19 months, despite growing friction in patient access that allegedly compromised the company's long-term outlook.

The class period concluded following an August 6, 2026, announcement where the company reduced its full-year 2026 revenue guidance for IBSRELA and withdrew long-term projections for XPHOZAH. The market reacted sharply to the news, with Ardelyx shares sliding from $4.87 to $4.00 in a single session—a decline of approximately 18%. Joseph E. Levi, representing the firm managing the action, stated that the chronology raises significant questions regarding exactly when internal leadership became aware of these market pressures and whether those challenges were intentionally obscured from investors.